nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisoprolol—CYP2D6—Tamoxifen—pancreatic cancer	0.0819	0.203	CbGbCtD
Bisoprolol—CYP2D6—Erlotinib—pancreatic cancer	0.0696	0.173	CbGbCtD
Bisoprolol—CYP3A4—Tamoxifen—pancreatic cancer	0.0521	0.129	CbGbCtD
Bisoprolol—CYP3A4—Erlotinib—pancreatic cancer	0.0443	0.11	CbGbCtD
Bisoprolol—CYP3A4—Irinotecan—pancreatic cancer	0.04	0.0994	CbGbCtD
Bisoprolol—CYP2D6—Doxorubicin—pancreatic cancer	0.0344	0.0854	CbGbCtD
Bisoprolol—CYP3A4—Docetaxel—pancreatic cancer	0.0293	0.0728	CbGbCtD
Bisoprolol—CYP3A4—Sunitinib—pancreatic cancer	0.0292	0.0725	CbGbCtD
Bisoprolol—CYP3A4—Doxorubicin—pancreatic cancer	0.0218	0.0543	CbGbCtD
Bisoprolol—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000426	0.000725	CcSEcCtD
Bisoprolol—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000426	0.000725	CcSEcCtD
Bisoprolol—Breast disorder—Doxorubicin—pancreatic cancer	0.000421	0.000717	CcSEcCtD
Bisoprolol—Body temperature increased—Irinotecan—pancreatic cancer	0.00042	0.000715	CcSEcCtD
Bisoprolol—Abdominal pain—Irinotecan—pancreatic cancer	0.00042	0.000715	CcSEcCtD
Bisoprolol—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.00042	0.000714	CcSEcCtD
Bisoprolol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000419	0.000713	CcSEcCtD
Bisoprolol—Bronchitis—Epirubicin—pancreatic cancer	0.000419	0.000713	CcSEcCtD
Bisoprolol—Gastritis—Doxorubicin—pancreatic cancer	0.000412	0.000702	CcSEcCtD
Bisoprolol—Muscular weakness—Doxorubicin—pancreatic cancer	0.000411	0.0007	CcSEcCtD
Bisoprolol—Vomiting—Sunitinib—pancreatic cancer	0.00041	0.000698	CcSEcCtD
Bisoprolol—Body temperature increased—Gemcitabine—pancreatic cancer	0.000409	0.000696	CcSEcCtD
Bisoprolol—Rash—Sunitinib—pancreatic cancer	0.000406	0.000692	CcSEcCtD
Bisoprolol—Dermatitis—Sunitinib—pancreatic cancer	0.000406	0.000691	CcSEcCtD
Bisoprolol—Urticaria—Fluorouracil—pancreatic cancer	0.000404	0.000688	CcSEcCtD
Bisoprolol—Headache—Sunitinib—pancreatic cancer	0.000404	0.000687	CcSEcCtD
Bisoprolol—Syncope—Docetaxel—pancreatic cancer	0.000403	0.000687	CcSEcCtD
Bisoprolol—Asthma—Doxorubicin—pancreatic cancer	0.000403	0.000686	CcSEcCtD
Bisoprolol—Body temperature increased—Fluorouracil—pancreatic cancer	0.000402	0.000684	CcSEcCtD
Bisoprolol—Palpitations—Docetaxel—pancreatic cancer	0.000397	0.000677	CcSEcCtD
Bisoprolol—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000397	0.000677	CcSEcCtD
Bisoprolol—Weight increased—Epirubicin—pancreatic cancer	0.000396	0.000675	CcSEcCtD
Bisoprolol—Loss of consciousness—Docetaxel—pancreatic cancer	0.000395	0.000673	CcSEcCtD
Bisoprolol—Cough—Docetaxel—pancreatic cancer	0.000392	0.000668	CcSEcCtD
Bisoprolol—Hypersensitivity—Irinotecan—pancreatic cancer	0.000391	0.000666	CcSEcCtD
Bisoprolol—Pneumonia—Epirubicin—pancreatic cancer	0.00039	0.000665	CcSEcCtD
Bisoprolol—Drowsiness—Epirubicin—pancreatic cancer	0.000388	0.000661	CcSEcCtD
Bisoprolol—Bronchitis—Doxorubicin—pancreatic cancer	0.000387	0.00066	CcSEcCtD
Bisoprolol—Myalgia—Docetaxel—pancreatic cancer	0.000383	0.000652	CcSEcCtD
Bisoprolol—Chest pain—Docetaxel—pancreatic cancer	0.000383	0.000652	CcSEcCtD
Bisoprolol—Arthralgia—Docetaxel—pancreatic cancer	0.000383	0.000652	CcSEcCtD
Bisoprolol—Nausea—Sunitinib—pancreatic cancer	0.000383	0.000652	CcSEcCtD
Bisoprolol—Asthenia—Irinotecan—pancreatic cancer	0.000381	0.000649	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.00038	0.000647	CcSEcCtD
Bisoprolol—Urinary tract infection—Epirubicin—pancreatic cancer	0.000377	0.000642	CcSEcCtD
Bisoprolol—Conjunctivitis—Epirubicin—pancreatic cancer	0.000377	0.000642	CcSEcCtD
Bisoprolol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000375	0.000638	CcSEcCtD
Bisoprolol—Dry mouth—Docetaxel—pancreatic cancer	0.000374	0.000637	CcSEcCtD
Bisoprolol—Sweating—Epirubicin—pancreatic cancer	0.000372	0.000634	CcSEcCtD
Bisoprolol—Asthenia—Gemcitabine—pancreatic cancer	0.000371	0.000632	CcSEcCtD
Bisoprolol—Confusional state—Docetaxel—pancreatic cancer	0.00037	0.00063	CcSEcCtD
Bisoprolol—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000368	0.000626	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000367	0.000625	CcSEcCtD
Bisoprolol—Oedema—Docetaxel—pancreatic cancer	0.000367	0.000625	CcSEcCtD
Bisoprolol—Weight increased—Doxorubicin—pancreatic cancer	0.000367	0.000624	CcSEcCtD
Bisoprolol—Pruritus—Gemcitabine—pancreatic cancer	0.000366	0.000623	CcSEcCtD
Bisoprolol—Infection—Docetaxel—pancreatic cancer	0.000365	0.000621	CcSEcCtD
Bisoprolol—Sinusitis—Epirubicin—pancreatic cancer	0.000364	0.00062	CcSEcCtD
Bisoprolol—Diarrhoea—Irinotecan—pancreatic cancer	0.000363	0.000618	CcSEcCtD
Bisoprolol—Agranulocytosis—Epirubicin—pancreatic cancer	0.000362	0.000617	CcSEcCtD
Bisoprolol—Pneumonia—Doxorubicin—pancreatic cancer	0.000361	0.000615	CcSEcCtD
Bisoprolol—Shock—Docetaxel—pancreatic cancer	0.000361	0.000615	CcSEcCtD
Bisoprolol—Nervous system disorder—Docetaxel—pancreatic cancer	0.00036	0.000613	CcSEcCtD
Bisoprolol—Pruritus—Fluorouracil—pancreatic cancer	0.00036	0.000613	CcSEcCtD
Bisoprolol—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000359	0.000612	CcSEcCtD
Bisoprolol—Drowsiness—Doxorubicin—pancreatic cancer	0.000359	0.000611	CcSEcCtD
Bisoprolol—Tachycardia—Docetaxel—pancreatic cancer	0.000358	0.00061	CcSEcCtD
Bisoprolol—Skin disorder—Docetaxel—pancreatic cancer	0.000357	0.000607	CcSEcCtD
Bisoprolol—Bradycardia—Epirubicin—pancreatic cancer	0.000355	0.000604	CcSEcCtD
Bisoprolol—Diarrhoea—Gemcitabine—pancreatic cancer	0.000354	0.000602	CcSEcCtD
Bisoprolol—Dizziness—Irinotecan—pancreatic cancer	0.000351	0.000598	CcSEcCtD
Bisoprolol—Rhinitis—Epirubicin—pancreatic cancer	0.000349	0.000595	CcSEcCtD
Bisoprolol—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000349	0.000594	CcSEcCtD
Bisoprolol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000349	0.000594	CcSEcCtD
Bisoprolol—Hepatitis—Epirubicin—pancreatic cancer	0.000348	0.000593	CcSEcCtD
Bisoprolol—Diarrhoea—Fluorouracil—pancreatic cancer	0.000348	0.000592	CcSEcCtD
Bisoprolol—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000347	0.00059	CcSEcCtD
Bisoprolol—Pharyngitis—Epirubicin—pancreatic cancer	0.000346	0.000589	CcSEcCtD
Bisoprolol—Sweating—Doxorubicin—pancreatic cancer	0.000344	0.000586	CcSEcCtD
Bisoprolol—Oedema peripheral—Epirubicin—pancreatic cancer	0.000343	0.000584	CcSEcCtD
Bisoprolol—Hypotension—Docetaxel—pancreatic cancer	0.000343	0.000584	CcSEcCtD
Bisoprolol—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000342	0.000583	CcSEcCtD
Bisoprolol—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.00034	0.000578	CcSEcCtD
Bisoprolol—Vomiting—Irinotecan—pancreatic cancer	0.000338	0.000575	CcSEcCtD
Bisoprolol—Sinusitis—Doxorubicin—pancreatic cancer	0.000337	0.000574	CcSEcCtD
Bisoprolol—Dizziness—Fluorouracil—pancreatic cancer	0.000336	0.000573	CcSEcCtD
Bisoprolol—Visual impairment—Epirubicin—pancreatic cancer	0.000336	0.000572	CcSEcCtD
Bisoprolol—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000335	0.000571	CcSEcCtD
Bisoprolol—Rash—Irinotecan—pancreatic cancer	0.000335	0.00057	CcSEcCtD
Bisoprolol—Dermatitis—Irinotecan—pancreatic cancer	0.000334	0.000569	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000334	0.000569	CcSEcCtD
Bisoprolol—Headache—Irinotecan—pancreatic cancer	0.000333	0.000566	CcSEcCtD
Bisoprolol—Insomnia—Docetaxel—pancreatic cancer	0.000332	0.000565	CcSEcCtD
Bisoprolol—Paraesthesia—Docetaxel—pancreatic cancer	0.00033	0.000561	CcSEcCtD
Bisoprolol—Vomiting—Gemcitabine—pancreatic cancer	0.000329	0.00056	CcSEcCtD
Bisoprolol—Bradycardia—Doxorubicin—pancreatic cancer	0.000328	0.000559	CcSEcCtD
Bisoprolol—Dyspnoea—Docetaxel—pancreatic cancer	0.000327	0.000557	CcSEcCtD
Bisoprolol—Somnolence—Docetaxel—pancreatic cancer	0.000326	0.000556	CcSEcCtD
Bisoprolol—Rash—Gemcitabine—pancreatic cancer	0.000326	0.000555	CcSEcCtD
Bisoprolol—Dermatitis—Gemcitabine—pancreatic cancer	0.000326	0.000555	CcSEcCtD
Bisoprolol—Eye disorder—Epirubicin—pancreatic cancer	0.000326	0.000554	CcSEcCtD
Bisoprolol—Tinnitus—Epirubicin—pancreatic cancer	0.000325	0.000553	CcSEcCtD
Bisoprolol—Headache—Gemcitabine—pancreatic cancer	0.000324	0.000552	CcSEcCtD
Bisoprolol—Flushing—Epirubicin—pancreatic cancer	0.000323	0.000551	CcSEcCtD
Bisoprolol—Cardiac disorder—Epirubicin—pancreatic cancer	0.000323	0.000551	CcSEcCtD
Bisoprolol—Vomiting—Fluorouracil—pancreatic cancer	0.000323	0.00055	CcSEcCtD
Bisoprolol—Rhinitis—Doxorubicin—pancreatic cancer	0.000323	0.00055	CcSEcCtD
Bisoprolol—Dyspepsia—Docetaxel—pancreatic cancer	0.000323	0.00055	CcSEcCtD
Bisoprolol—Hepatitis—Doxorubicin—pancreatic cancer	0.000322	0.000549	CcSEcCtD
Bisoprolol—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000321	0.000546	CcSEcCtD
Bisoprolol—Rash—Fluorouracil—pancreatic cancer	0.000321	0.000546	CcSEcCtD
Bisoprolol—Dermatitis—Fluorouracil—pancreatic cancer	0.00032	0.000545	CcSEcCtD
Bisoprolol—Pharyngitis—Doxorubicin—pancreatic cancer	0.00032	0.000545	CcSEcCtD
Bisoprolol—Headache—Fluorouracil—pancreatic cancer	0.000319	0.000542	CcSEcCtD
Bisoprolol—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000318	0.000541	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000317	0.000539	CcSEcCtD
Bisoprolol—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000317	0.000539	CcSEcCtD
Bisoprolol—Fatigue—Docetaxel—pancreatic cancer	0.000316	0.000539	CcSEcCtD
Bisoprolol—Angiopathy—Epirubicin—pancreatic cancer	0.000316	0.000538	CcSEcCtD
Bisoprolol—Nausea—Irinotecan—pancreatic cancer	0.000315	0.000537	CcSEcCtD
Bisoprolol—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000314	0.000535	CcSEcCtD
Bisoprolol—Pain—Docetaxel—pancreatic cancer	0.000314	0.000534	CcSEcCtD
Bisoprolol—Constipation—Docetaxel—pancreatic cancer	0.000314	0.000534	CcSEcCtD
Bisoprolol—Arrhythmia—Epirubicin—pancreatic cancer	0.000311	0.00053	CcSEcCtD
Bisoprolol—Visual impairment—Doxorubicin—pancreatic cancer	0.000311	0.000529	CcSEcCtD
Bisoprolol—Alopecia—Epirubicin—pancreatic cancer	0.000308	0.000524	CcSEcCtD
Bisoprolol—Nausea—Gemcitabine—pancreatic cancer	0.000307	0.000523	CcSEcCtD
Bisoprolol—Mental disorder—Epirubicin—pancreatic cancer	0.000305	0.00052	CcSEcCtD
Bisoprolol—Erythema—Epirubicin—pancreatic cancer	0.000303	0.000516	CcSEcCtD
Bisoprolol—Feeling abnormal—Docetaxel—pancreatic cancer	0.000302	0.000515	CcSEcCtD
Bisoprolol—Nausea—Fluorouracil—pancreatic cancer	0.000302	0.000514	CcSEcCtD
Bisoprolol—Eye disorder—Doxorubicin—pancreatic cancer	0.000301	0.000513	CcSEcCtD
Bisoprolol—Tinnitus—Doxorubicin—pancreatic cancer	0.000301	0.000512	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.0003	0.000511	CcSEcCtD
Bisoprolol—Flushing—Doxorubicin—pancreatic cancer	0.000299	0.000509	CcSEcCtD
Bisoprolol—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000299	0.000509	CcSEcCtD
Bisoprolol—Dysgeusia—Epirubicin—pancreatic cancer	0.000297	0.000506	CcSEcCtD
Bisoprolol—Back pain—Epirubicin—pancreatic cancer	0.000293	0.0005	CcSEcCtD
Bisoprolol—Angiopathy—Doxorubicin—pancreatic cancer	0.000293	0.000498	CcSEcCtD
Bisoprolol—Muscle spasms—Epirubicin—pancreatic cancer	0.000292	0.000497	CcSEcCtD
Bisoprolol—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000291	0.000495	CcSEcCtD
Bisoprolol—Body temperature increased—Docetaxel—pancreatic cancer	0.00029	0.000494	CcSEcCtD
Bisoprolol—Abdominal pain—Docetaxel—pancreatic cancer	0.00029	0.000494	CcSEcCtD
Bisoprolol—Arrhythmia—Doxorubicin—pancreatic cancer	0.000288	0.00049	CcSEcCtD
Bisoprolol—Alopecia—Doxorubicin—pancreatic cancer	0.000285	0.000485	CcSEcCtD
Bisoprolol—Mental disorder—Doxorubicin—pancreatic cancer	0.000282	0.000481	CcSEcCtD
Bisoprolol—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000281	0.000479	CcSEcCtD
Bisoprolol—Erythema—Doxorubicin—pancreatic cancer	0.000281	0.000478	CcSEcCtD
Bisoprolol—Agitation—Epirubicin—pancreatic cancer	0.000279	0.000475	CcSEcCtD
Bisoprolol—Dysgeusia—Doxorubicin—pancreatic cancer	0.000275	0.000468	CcSEcCtD
Bisoprolol—Malaise—Epirubicin—pancreatic cancer	0.000274	0.000466	CcSEcCtD
Bisoprolol—Vertigo—Epirubicin—pancreatic cancer	0.000273	0.000464	CcSEcCtD
Bisoprolol—Syncope—Epirubicin—pancreatic cancer	0.000272	0.000463	CcSEcCtD
Bisoprolol—Back pain—Doxorubicin—pancreatic cancer	0.000271	0.000462	CcSEcCtD
Bisoprolol—Hypersensitivity—Docetaxel—pancreatic cancer	0.00027	0.00046	CcSEcCtD
Bisoprolol—Muscle spasms—Doxorubicin—pancreatic cancer	0.00027	0.000459	CcSEcCtD
Bisoprolol—Palpitations—Epirubicin—pancreatic cancer	0.000268	0.000456	CcSEcCtD
Bisoprolol—Loss of consciousness—Epirubicin—pancreatic cancer	0.000267	0.000454	CcSEcCtD
Bisoprolol—Cough—Epirubicin—pancreatic cancer	0.000265	0.000451	CcSEcCtD
Bisoprolol—Asthenia—Docetaxel—pancreatic cancer	0.000263	0.000448	CcSEcCtD
Bisoprolol—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.00026	0.000443	CcSEcCtD
Bisoprolol—Pruritus—Docetaxel—pancreatic cancer	0.00026	0.000442	CcSEcCtD
Bisoprolol—Chest pain—Epirubicin—pancreatic cancer	0.000258	0.00044	CcSEcCtD
Bisoprolol—Myalgia—Epirubicin—pancreatic cancer	0.000258	0.00044	CcSEcCtD
Bisoprolol—Arthralgia—Epirubicin—pancreatic cancer	0.000258	0.00044	CcSEcCtD
Bisoprolol—Agitation—Doxorubicin—pancreatic cancer	0.000258	0.000439	CcSEcCtD
Bisoprolol—Anxiety—Epirubicin—pancreatic cancer	0.000257	0.000438	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000256	0.000437	CcSEcCtD
Bisoprolol—Discomfort—Epirubicin—pancreatic cancer	0.000255	0.000434	CcSEcCtD
Bisoprolol—Malaise—Doxorubicin—pancreatic cancer	0.000253	0.000431	CcSEcCtD
Bisoprolol—Dry mouth—Epirubicin—pancreatic cancer	0.000253	0.00043	CcSEcCtD
Bisoprolol—Vertigo—Doxorubicin—pancreatic cancer	0.000252	0.000429	CcSEcCtD
Bisoprolol—Syncope—Doxorubicin—pancreatic cancer	0.000252	0.000429	CcSEcCtD
Bisoprolol—Diarrhoea—Docetaxel—pancreatic cancer	0.000251	0.000428	CcSEcCtD
Bisoprolol—Confusional state—Epirubicin—pancreatic cancer	0.00025	0.000425	CcSEcCtD
Bisoprolol—Palpitations—Doxorubicin—pancreatic cancer	0.000248	0.000422	CcSEcCtD
Bisoprolol—Oedema—Epirubicin—pancreatic cancer	0.000248	0.000421	CcSEcCtD
Bisoprolol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000247	0.00042	CcSEcCtD
Bisoprolol—Infection—Epirubicin—pancreatic cancer	0.000246	0.000419	CcSEcCtD
Bisoprolol—Cough—Doxorubicin—pancreatic cancer	0.000245	0.000417	CcSEcCtD
Bisoprolol—Shock—Epirubicin—pancreatic cancer	0.000244	0.000415	CcSEcCtD
Bisoprolol—Nervous system disorder—Epirubicin—pancreatic cancer	0.000243	0.000413	CcSEcCtD
Bisoprolol—Dizziness—Docetaxel—pancreatic cancer	0.000243	0.000413	CcSEcCtD
Bisoprolol—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000242	0.000413	CcSEcCtD
Bisoprolol—Tachycardia—Epirubicin—pancreatic cancer	0.000242	0.000411	CcSEcCtD
Bisoprolol—Skin disorder—Epirubicin—pancreatic cancer	0.00024	0.000409	CcSEcCtD
Bisoprolol—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000239	0.000407	CcSEcCtD
Bisoprolol—Chest pain—Doxorubicin—pancreatic cancer	0.000239	0.000407	CcSEcCtD
Bisoprolol—Myalgia—Doxorubicin—pancreatic cancer	0.000239	0.000407	CcSEcCtD
Bisoprolol—Arthralgia—Doxorubicin—pancreatic cancer	0.000239	0.000407	CcSEcCtD
Bisoprolol—Anxiety—Doxorubicin—pancreatic cancer	0.000238	0.000405	CcSEcCtD
Bisoprolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000237	0.000404	CcSEcCtD
Bisoprolol—Discomfort—Doxorubicin—pancreatic cancer	0.000236	0.000402	CcSEcCtD
Bisoprolol—Dry mouth—Doxorubicin—pancreatic cancer	0.000234	0.000398	CcSEcCtD
Bisoprolol—Vomiting—Docetaxel—pancreatic cancer	0.000233	0.000397	CcSEcCtD
Bisoprolol—Rash—Docetaxel—pancreatic cancer	0.000231	0.000394	CcSEcCtD
Bisoprolol—Hypotension—Epirubicin—pancreatic cancer	0.000231	0.000394	CcSEcCtD
Bisoprolol—Dermatitis—Docetaxel—pancreatic cancer	0.000231	0.000394	CcSEcCtD
Bisoprolol—Confusional state—Doxorubicin—pancreatic cancer	0.000231	0.000393	CcSEcCtD
Bisoprolol—Headache—Docetaxel—pancreatic cancer	0.00023	0.000391	CcSEcCtD
Bisoprolol—Oedema—Doxorubicin—pancreatic cancer	0.000229	0.00039	CcSEcCtD
Bisoprolol—Infection—Doxorubicin—pancreatic cancer	0.000228	0.000387	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000226	0.000384	CcSEcCtD
Bisoprolol—Shock—Doxorubicin—pancreatic cancer	0.000225	0.000384	CcSEcCtD
Bisoprolol—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000225	0.000382	CcSEcCtD
Bisoprolol—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000224	0.000382	CcSEcCtD
Bisoprolol—Insomnia—Epirubicin—pancreatic cancer	0.000224	0.000381	CcSEcCtD
Bisoprolol—Tachycardia—Doxorubicin—pancreatic cancer	0.000224	0.000381	CcSEcCtD
Bisoprolol—Skin disorder—Doxorubicin—pancreatic cancer	0.000222	0.000379	CcSEcCtD
Bisoprolol—Paraesthesia—Epirubicin—pancreatic cancer	0.000222	0.000378	CcSEcCtD
Bisoprolol—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000221	0.000377	CcSEcCtD
Bisoprolol—Dyspnoea—Epirubicin—pancreatic cancer	0.000221	0.000376	CcSEcCtD
Bisoprolol—Somnolence—Epirubicin—pancreatic cancer	0.00022	0.000375	CcSEcCtD
Bisoprolol—Nausea—Docetaxel—pancreatic cancer	0.000218	0.000371	CcSEcCtD
Bisoprolol—Dyspepsia—Epirubicin—pancreatic cancer	0.000218	0.000371	CcSEcCtD
Bisoprolol—Hypotension—Doxorubicin—pancreatic cancer	0.000214	0.000364	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000214	0.000364	CcSEcCtD
Bisoprolol—Fatigue—Epirubicin—pancreatic cancer	0.000213	0.000363	CcSEcCtD
Bisoprolol—Pain—Epirubicin—pancreatic cancer	0.000212	0.00036	CcSEcCtD
Bisoprolol—Constipation—Epirubicin—pancreatic cancer	0.000212	0.00036	CcSEcCtD
Bisoprolol—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000209	0.000355	CcSEcCtD
Bisoprolol—Insomnia—Doxorubicin—pancreatic cancer	0.000207	0.000353	CcSEcCtD
Bisoprolol—Paraesthesia—Doxorubicin—pancreatic cancer	0.000206	0.00035	CcSEcCtD
Bisoprolol—Dyspnoea—Doxorubicin—pancreatic cancer	0.000204	0.000348	CcSEcCtD
Bisoprolol—Feeling abnormal—Epirubicin—pancreatic cancer	0.000204	0.000347	CcSEcCtD
Bisoprolol—Somnolence—Doxorubicin—pancreatic cancer	0.000204	0.000347	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000202	0.000345	CcSEcCtD
Bisoprolol—Dyspepsia—Doxorubicin—pancreatic cancer	0.000202	0.000343	CcSEcCtD
Bisoprolol—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000198	0.000337	CcSEcCtD
Bisoprolol—Fatigue—Doxorubicin—pancreatic cancer	0.000197	0.000336	CcSEcCtD
Bisoprolol—Urticaria—Epirubicin—pancreatic cancer	0.000197	0.000335	CcSEcCtD
Bisoprolol—Constipation—Doxorubicin—pancreatic cancer	0.000196	0.000333	CcSEcCtD
Bisoprolol—Pain—Doxorubicin—pancreatic cancer	0.000196	0.000333	CcSEcCtD
Bisoprolol—Body temperature increased—Epirubicin—pancreatic cancer	0.000196	0.000333	CcSEcCtD
Bisoprolol—Abdominal pain—Epirubicin—pancreatic cancer	0.000196	0.000333	CcSEcCtD
Bisoprolol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000189	0.000321	CcSEcCtD
Bisoprolol—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000187	0.000319	CcSEcCtD
Bisoprolol—Hypersensitivity—Epirubicin—pancreatic cancer	0.000182	0.000311	CcSEcCtD
Bisoprolol—Urticaria—Doxorubicin—pancreatic cancer	0.000182	0.00031	CcSEcCtD
Bisoprolol—Abdominal pain—Doxorubicin—pancreatic cancer	0.000181	0.000308	CcSEcCtD
Bisoprolol—Body temperature increased—Doxorubicin—pancreatic cancer	0.000181	0.000308	CcSEcCtD
Bisoprolol—Asthenia—Epirubicin—pancreatic cancer	0.000178	0.000302	CcSEcCtD
Bisoprolol—Pruritus—Epirubicin—pancreatic cancer	0.000175	0.000298	CcSEcCtD
Bisoprolol—Diarrhoea—Epirubicin—pancreatic cancer	0.000169	0.000288	CcSEcCtD
Bisoprolol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000169	0.000287	CcSEcCtD
Bisoprolol—Asthenia—Doxorubicin—pancreatic cancer	0.000164	0.00028	CcSEcCtD
Bisoprolol—Dizziness—Epirubicin—pancreatic cancer	0.000164	0.000279	CcSEcCtD
Bisoprolol—Pruritus—Doxorubicin—pancreatic cancer	0.000162	0.000276	CcSEcCtD
Bisoprolol—Vomiting—Epirubicin—pancreatic cancer	0.000157	0.000268	CcSEcCtD
Bisoprolol—Diarrhoea—Doxorubicin—pancreatic cancer	0.000157	0.000267	CcSEcCtD
Bisoprolol—Rash—Epirubicin—pancreatic cancer	0.000156	0.000266	CcSEcCtD
Bisoprolol—Dermatitis—Epirubicin—pancreatic cancer	0.000156	0.000265	CcSEcCtD
Bisoprolol—Headache—Epirubicin—pancreatic cancer	0.000155	0.000264	CcSEcCtD
Bisoprolol—Dizziness—Doxorubicin—pancreatic cancer	0.000151	0.000258	CcSEcCtD
Bisoprolol—Nausea—Epirubicin—pancreatic cancer	0.000147	0.00025	CcSEcCtD
Bisoprolol—Vomiting—Doxorubicin—pancreatic cancer	0.000146	0.000248	CcSEcCtD
Bisoprolol—Rash—Doxorubicin—pancreatic cancer	0.000144	0.000246	CcSEcCtD
Bisoprolol—Dermatitis—Doxorubicin—pancreatic cancer	0.000144	0.000246	CcSEcCtD
Bisoprolol—Headache—Doxorubicin—pancreatic cancer	0.000143	0.000244	CcSEcCtD
Bisoprolol—Nausea—Doxorubicin—pancreatic cancer	0.000136	0.000232	CcSEcCtD
Bisoprolol—ADRB1—GPCR downstream signaling—CNR2—pancreatic cancer	2.21e-05	0.0022	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—GLP1R—pancreatic cancer	2.21e-05	0.0022	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CCKAR—pancreatic cancer	2.17e-05	0.00216	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CNR2—pancreatic cancer	2.16e-05	0.00215	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—GLP1R—pancreatic cancer	2.16e-05	0.00215	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—SCT—pancreatic cancer	2.16e-05	0.00215	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CCKAR—pancreatic cancer	2.13e-05	0.00211	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—SCT—pancreatic cancer	2.11e-05	0.0021	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PRLHR—pancreatic cancer	2.06e-05	0.00205	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CCK—pancreatic cancer	2.06e-05	0.00205	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PRLHR—pancreatic cancer	2.02e-05	0.00201	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CCK—pancreatic cancer	2.02e-05	0.002	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CNR2—pancreatic cancer	2.01e-05	0.00199	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—GLP1R—pancreatic cancer	2.01e-05	0.00199	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CCKAR—pancreatic cancer	1.97e-05	0.00196	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CNR2—pancreatic cancer	1.96e-05	0.00195	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—GLP1R—pancreatic cancer	1.96e-05	0.00195	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—IAPP—pancreatic cancer	1.96e-05	0.00195	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ZNRF3—pancreatic cancer	1.94e-05	0.00193	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—ACVR1B—pancreatic cancer	1.94e-05	0.00193	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CCKAR—pancreatic cancer	1.93e-05	0.00192	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—IAPP—pancreatic cancer	1.92e-05	0.0019	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ACVR1B—pancreatic cancer	1.9e-05	0.00189	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—ZNRF3—pancreatic cancer	1.9e-05	0.00189	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PTHLH—pancreatic cancer	1.88e-05	0.00187	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PTHLH—pancreatic cancer	1.84e-05	0.00183	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—SHH—pancreatic cancer	1.8e-05	0.00179	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—IAPP—pancreatic cancer	1.78e-05	0.00177	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—SHH—pancreatic cancer	1.76e-05	0.00175	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SSTR3—pancreatic cancer	1.76e-05	0.00174	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—DTX1—pancreatic cancer	1.76e-05	0.00174	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—IAPP—pancreatic cancer	1.74e-05	0.00173	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—SST—pancreatic cancer	1.72e-05	0.00171	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SSTR3—pancreatic cancer	1.72e-05	0.00171	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—DTX1—pancreatic cancer	1.72e-05	0.00171	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PTHLH—pancreatic cancer	1.71e-05	0.0017	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PTCH1—pancreatic cancer	1.71e-05	0.0017	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SSTR1—pancreatic cancer	1.68e-05	0.00167	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—SST—pancreatic cancer	1.68e-05	0.00167	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PTCH1—pancreatic cancer	1.67e-05	0.00166	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PTHLH—pancreatic cancer	1.67e-05	0.00166	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PPY—pancreatic cancer	1.65e-05	0.00164	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SSTR1—pancreatic cancer	1.65e-05	0.00164	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SSTR2—pancreatic cancer	1.62e-05	0.00161	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PPY—pancreatic cancer	1.61e-05	0.0016	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CNR1—pancreatic cancer	1.59e-05	0.00158	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SSTR2—pancreatic cancer	1.58e-05	0.00157	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCKBR—pancreatic cancer	1.56e-05	0.00155	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—SST—pancreatic cancer	1.56e-05	0.00155	CbGpPWpGaD
Bisoprolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.56e-05	0.00155	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CNR1—pancreatic cancer	1.55e-05	0.00154	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—GCG—pancreatic cancer	1.53e-05	0.00152	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCKBR—pancreatic cancer	1.53e-05	0.00152	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—SST—pancreatic cancer	1.53e-05	0.00152	CbGpPWpGaD
Bisoprolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.52e-05	0.00151	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—GCG—pancreatic cancer	1.5e-05	0.00149	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GLI1—pancreatic cancer	1.47e-05	0.00146	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—DTX4—pancreatic cancer	1.47e-05	0.00146	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AGTR1—pancreatic cancer	1.46e-05	0.00145	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CNR1—pancreatic cancer	1.44e-05	0.00143	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—DTX4—pancreatic cancer	1.44e-05	0.00143	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GLI1—pancreatic cancer	1.44e-05	0.00143	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PPP2R5B—pancreatic cancer	1.43e-05	0.00142	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NRP1—pancreatic cancer	1.43e-05	0.00142	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AGTR1—pancreatic cancer	1.43e-05	0.00142	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CNR1—pancreatic cancer	1.41e-05	0.0014	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NRP1—pancreatic cancer	1.4e-05	0.00139	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PPP2R5B—pancreatic cancer	1.4e-05	0.00139	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—GCG—pancreatic cancer	1.39e-05	0.00138	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HEY2—pancreatic cancer	1.38e-05	0.00137	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—GCG—pancreatic cancer	1.36e-05	0.00135	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HEY2—pancreatic cancer	1.35e-05	0.00134	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GAST—pancreatic cancer	1.35e-05	0.00134	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AGTR1—pancreatic cancer	1.33e-05	0.00132	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GAST—pancreatic cancer	1.32e-05	0.00131	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AGTR1—pancreatic cancer	1.3e-05	0.00129	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HEY1—pancreatic cancer	1.28e-05	0.00127	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SCT—pancreatic cancer	1.28e-05	0.00127	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SCT—pancreatic cancer	1.25e-05	0.00124	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HEY1—pancreatic cancer	1.25e-05	0.00124	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCK—pancreatic cancer	1.22e-05	0.00121	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCK—pancreatic cancer	1.19e-05	0.00118	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CNR2—pancreatic cancer	1.19e-05	0.00118	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GLP1R—pancreatic cancer	1.19e-05	0.00118	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR ligand binding—CXCL8—pancreatic cancer	1.19e-05	0.00118	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCKAR—pancreatic cancer	1.17e-05	0.00116	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CNR2—pancreatic cancer	1.16e-05	0.00115	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GLP1R—pancreatic cancer	1.16e-05	0.00115	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR ligand binding—CXCL8—pancreatic cancer	1.16e-05	0.00115	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCKAR—pancreatic cancer	1.14e-05	0.00113	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PRSS1—pancreatic cancer	1.14e-05	0.00113	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JAG2—pancreatic cancer	1.13e-05	0.00112	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MEN1—pancreatic cancer	1.11e-05	0.00111	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JAG2—pancreatic cancer	1.11e-05	0.0011	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MEN1—pancreatic cancer	1.09e-05	0.00108	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SHH—pancreatic cancer	1.06e-05	0.00106	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOTCH4—pancreatic cancer	1.06e-05	0.00105	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—IAPP—pancreatic cancer	1.05e-05	0.00104	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SHH—pancreatic cancer	1.04e-05	0.00103	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOTCH4—pancreatic cancer	1.03e-05	0.00103	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—IAPP—pancreatic cancer	1.03e-05	0.00102	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTCH1—pancreatic cancer	1.01e-05	0.001	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTHLH—pancreatic cancer	1.01e-05	0.001	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTHLH—pancreatic cancer	9.86e-06	0.00098	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTCH1—pancreatic cancer	9.86e-06	0.00098	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—ARG2—pancreatic cancer	9.86e-06	0.00098	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SST—pancreatic cancer	9.22e-06	0.000916	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.1e-06	0.000904	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—JAG1—pancreatic cancer	9.03e-06	0.000897	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SST—pancreatic cancer	9.02e-06	0.000896	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOTCH3—pancreatic cancer	8.99e-06	0.000893	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CG—pancreatic cancer	8.9e-06	0.000884	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—JAG1—pancreatic cancer	8.83e-06	0.000877	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOTCH3—pancreatic cancer	8.79e-06	0.000873	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TYMP—pancreatic cancer	8.62e-06	0.000856	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CNR1—pancreatic cancer	8.51e-06	0.000846	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CNR1—pancreatic cancer	8.33e-06	0.000827	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CG—pancreatic cancer	8.26e-06	0.000821	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—GCG—pancreatic cancer	8.22e-06	0.000817	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CG—pancreatic cancer	8.08e-06	0.000803	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—GCG—pancreatic cancer	8.04e-06	0.000799	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CD—pancreatic cancer	8e-06	0.000794	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AGTR1—pancreatic cancer	7.84e-06	0.000779	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.82e-06	0.000777	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STK11—pancreatic cancer	7.73e-06	0.000768	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AGTR1—pancreatic cancer	7.67e-06	0.000762	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STK11—pancreatic cancer	7.56e-06	0.000751	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PRSS1—pancreatic cancer	7.44e-06	0.000739	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CD—pancreatic cancer	7.26e-06	0.000721	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CD—pancreatic cancer	7.1e-06	0.000706	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.97e-06	0.000692	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GLP1R—pancreatic cancer	6.95e-06	0.00069	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—DPYD—pancreatic cancer	6.84e-06	0.000679	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.82e-06	0.000677	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SMAD4—pancreatic cancer	6.77e-06	0.000673	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—CXCL8—pancreatic cancer	6.7e-06	0.000665	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SMAD4—pancreatic cancer	6.62e-06	0.000658	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HES1—pancreatic cancer	6.61e-06	0.000657	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—CXCL8—pancreatic cancer	6.55e-06	0.000651	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—SLC2A2—pancreatic cancer	6.49e-06	0.000644	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HES1—pancreatic cancer	6.47e-06	0.000642	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—ARG2—pancreatic cancer	6.45e-06	0.000641	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CB—pancreatic cancer	6.33e-06	0.000629	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CB—pancreatic cancer	6.19e-06	0.000615	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—CXCL8—pancreatic cancer	6.08e-06	0.000604	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—CXCL8—pancreatic cancer	5.95e-06	0.000591	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TERT—pancreatic cancer	5.79e-06	0.000575	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TERT—pancreatic cancer	5.67e-06	0.000563	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TYMP—pancreatic cancer	5.64e-06	0.00056	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HIF1A—pancreatic cancer	5.54e-06	0.00055	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TSC2—pancreatic cancer	5.52e-06	0.000549	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HIF1A—pancreatic cancer	5.42e-06	0.000538	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—APOE—pancreatic cancer	5.41e-06	0.000537	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TSC2—pancreatic cancer	5.4e-06	0.000537	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KDR—pancreatic cancer	5.3e-06	0.000526	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—APOE—pancreatic cancer	5.29e-06	0.000525	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KDR—pancreatic cancer	5.18e-06	0.000515	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NFKBIA—pancreatic cancer	5.04e-06	0.000501	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—CD44—pancreatic cancer	5.02e-06	0.000499	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NOTCH1—pancreatic cancer	4.99e-06	0.000496	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NFKBIA—pancreatic cancer	4.93e-06	0.00049	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NOTCH1—pancreatic cancer	4.88e-06	0.000485	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CG—pancreatic cancer	4.88e-06	0.000485	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—NRAS—pancreatic cancer	4.88e-06	0.000485	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGF—pancreatic cancer	4.82e-06	0.000479	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—GCG—pancreatic cancer	4.82e-06	0.000478	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CG—pancreatic cancer	4.77e-06	0.000474	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—NRAS—pancreatic cancer	4.77e-06	0.000474	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGF—pancreatic cancer	4.72e-06	0.000469	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.54e-06	0.000451	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—STK11—pancreatic cancer	4.53e-06	0.00045	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—DPYD—pancreatic cancer	4.47e-06	0.000444	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—EGFR—pancreatic cancer	4.45e-06	0.000442	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—EGFR—pancreatic cancer	4.35e-06	0.000432	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CD—pancreatic cancer	4.29e-06	0.000426	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.25e-06	0.000422	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	4.24e-06	0.000421	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—KRAS—pancreatic cancer	4.2e-06	0.000417	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CD—pancreatic cancer	4.2e-06	0.000417	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.16e-06	0.000413	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—KRAS—pancreatic cancer	4.11e-06	0.000408	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—TYMS—pancreatic cancer	3.89e-06	0.000387	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.86e-06	0.000383	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—PIK3CA—pancreatic cancer	3.77e-06	0.000375	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CB—pancreatic cancer	3.74e-06	0.000371	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CB—pancreatic cancer	3.66e-06	0.000363	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CXCL8—pancreatic cancer	3.59e-06	0.000357	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—HRAS—pancreatic cancer	3.57e-06	0.000355	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CXCL8—pancreatic cancer	3.51e-06	0.000349	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—HRAS—pancreatic cancer	3.49e-06	0.000347	CbGpPWpGaD
Bisoprolol—ADRB1—GPCR downstream signaling—AKT1—pancreatic cancer	3.47e-06	0.000345	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CASP3—pancreatic cancer	3.44e-06	0.000342	CbGpPWpGaD
Bisoprolol—ADRB2—GPCR downstream signaling—AKT1—pancreatic cancer	3.4e-06	0.000337	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CASP3—pancreatic cancer	3.36e-06	0.000334	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CCND1—pancreatic cancer	3.35e-06	0.000333	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—CTNNB1—pancreatic cancer	3.31e-06	0.000329	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—CD44—pancreatic cancer	3.28e-06	0.000326	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CCND1—pancreatic cancer	3.27e-06	0.000325	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MMP9—pancreatic cancer	3.25e-06	0.000323	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—CTNNB1—pancreatic cancer	3.24e-06	0.000322	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PTEN—pancreatic cancer	3.23e-06	0.000321	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MMP9—pancreatic cancer	3.18e-06	0.000316	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—APOE—pancreatic cancer	3.17e-06	0.000315	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PTEN—pancreatic cancer	3.16e-06	0.000314	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling by GPCR—AKT1—pancreatic cancer	3.15e-06	0.000313	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—GCG—pancreatic cancer	3.15e-06	0.000313	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	3.08e-06	0.000306	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—SRC—pancreatic cancer	3e-06	0.000298	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—STK11—pancreatic cancer	2.96e-06	0.000294	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—SRC—pancreatic cancer	2.93e-06	0.000291	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	2.92e-06	0.00029	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	2.89e-06	0.000287	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	2.88e-06	0.000286	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	2.86e-06	0.000284	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	2.85e-06	0.000284	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	2.83e-06	0.000281	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	2.82e-06	0.00028	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PPARG—pancreatic cancer	2.76e-06	0.000274	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—MYC—pancreatic cancer	2.68e-06	0.000267	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	2.68e-06	0.000266	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—MYC—pancreatic cancer	2.63e-06	0.000261	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	2.63e-06	0.000261	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	2.62e-06	0.00026	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	2.57e-06	0.000255	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.55e-06	0.000253	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	2.51e-06	0.00025	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	2.48e-06	0.000246	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	2.43e-06	0.000241	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	2.28e-06	0.000226	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	2.23e-06	0.000222	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—TP53—pancreatic cancer	2.2e-06	0.000219	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	2.19e-06	0.000218	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTGS2—pancreatic cancer	2.17e-06	0.000216	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—TP53—pancreatic cancer	2.16e-06	0.000214	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	2.11e-06	0.00021	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—APOE—pancreatic cancer	2.07e-06	0.000206	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	2.06e-06	0.000205	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PTEN—pancreatic cancer	1.89e-06	0.000188	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.87e-06	0.000186	CbGpPWpGaD
Bisoprolol—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	1.86e-06	0.000185	CbGpPWpGaD
Bisoprolol—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	1.82e-06	0.000181	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.8e-06	0.000179	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.64e-06	0.000163	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.43e-06	0.000142	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.42e-06	0.000141	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	1.34e-06	0.000133	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.24e-06	0.000123	CbGpPWpGaD
Bisoprolol—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.09e-06	0.000108	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	8.73e-07	8.67e-05	CbGpPWpGaD
Bisoprolol—CYP3A4—Metabolism—AKT1—pancreatic cancer	7.13e-07	7.09e-05	CbGpPWpGaD
